CA3277013A1 - Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation - Google Patents

Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Info

Publication number
CA3277013A1
CA3277013A1 CA3277013A CA3277013A CA3277013A1 CA 3277013 A1 CA3277013 A1 CA 3277013A1 CA 3277013 A CA3277013 A CA 3277013A CA 3277013 A CA3277013 A CA 3277013A CA 3277013 A1 CA3277013 A1 CA 3277013A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
die
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3277013A
Other languages
English (en)
Inventor
Jeremy S. Myers
Eric M. Tam
Mohosin Sarkar
Guixian Jin
Xingyue AN
Stella Aviaty Martomo
Original Assignee
EvolveImmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EvolveImmune Therapeutics Inc filed Critical EvolveImmune Therapeutics Inc
Publication of CA3277013A1 publication Critical patent/CA3277013A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps bispécifiques ou des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement à CD3 et CD20. Les anticorps sont éventuellement fusionnés avec un peptide CD58 ou des parties de celui-ci. L'invention concerne des procédés de fabrication et d'utilisation des anticorps bispécifiques pour le traitement de cancers qui expriment CD20.
CA3277013A 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation Pending CA3277013A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263432665P 2022-12-14 2022-12-14
US63/432,665 2022-12-14
PCT/US2023/084129 WO2024130032A1 (fr) 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3277013A1 true CA3277013A1 (fr) 2024-06-20

Family

ID=89983446

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3277013A Pending CA3277013A1 (fr) 2022-12-14 2023-12-14 Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Country Status (5)

Country Link
EP (1) EP4634228A1 (fr)
AU (1) AU2023398887A1 (fr)
CA (1) CA3277013A1 (fr)
IL (1) IL321437A (fr)
WO (1) WO2024130032A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026076258A1 (fr) * 2024-10-03 2026-04-09 Evolveimmune Therapeutics, Inc. Molécules de fusion d'anticorps bispécifique ciblant cd20 et cd3 et leurs procédés d'utilisation
WO2026158365A1 (fr) * 2025-01-22 2026-07-30 上海齐鲁制药研究中心有限公司 Molécule de liaison à l'antigène trispécifique et son utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743809T3 (es) * 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
US10428155B2 (en) * 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
CN107660214B (zh) * 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CN108290958B (zh) * 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
EP4493593A1 (fr) * 2022-03-18 2025-01-22 Evolveimmune Therapeutics, Inc. Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2024130032A1 (fr) 2024-06-20
IL321437A (en) 2025-08-01
AU2023398887A1 (en) 2025-06-26
EP4634228A1 (fr) 2025-10-22

Similar Documents

Publication Publication Date Title
US20230406946A1 (en) Antibodies and methods of use thereof
US20220389107A1 (en) Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US20230279117A1 (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
US20210371537A1 (en) Anti-tnfr2 antibodies and uses thereof
US20250197496A1 (en) Bispecific antibody fusion molecules and methods of use thereof
US12435151B2 (en) Anti-TNFR2 antibodies and uses thereof
WO2024130032A1 (fr) Molécules de fusion d'anticorps bispécifiques et leurs procédés d'utilisation
WO2025064890A1 (fr) Molécules de fusion d'anticorps bispécifiques ciblant cd180 et cd3 et leurs méthodes d'utilisation
WO2024258870A2 (fr) Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
WO2026076258A1 (fr) Molécules de fusion d'anticorps bispécifique ciblant cd20 et cd3 et leurs procédés d'utilisation
AU2024345039A1 (en) Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
WO2025059037A9 (fr) Molécules de fusion d'anticorps bispécifiques ciblant b7-h4 et cd3 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250613

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250613

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250613

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250613

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250613

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250619

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250619

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260528